Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced ...

Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to treat hyperphagia and obesity. Rhythm is evaluating setmelanotide in a global Phase 3 trial in patients with acquired hypothalamic ...

Competing Interests: The authors declared no competing interests. Monogenic hypertension is caused by single gene mutations and accounts for a spectrum of familial forms of elevated blood pressure ...

Patients can now easily buy these tests, but cardiologists must consider their quality when using the information to guide ...

Interactive Tool Harnesses Real-World Data to Visualize Burden of Disease in HCM and Advance Equitable Access to CareSOUTH SAN FRANCISCO, Calif., ...

We recently shared a list of 10 Best Short Squeeze Stocks To Buy According to Analysts. In this article, we will see how ...

Giulio Cossu, MD, speaks to the lingering safety concerns related to ex vivo gene therapy in Duchenne muscular dystrophy (DMD) as long-term data are yet to be established.

Needham & Company LLC reiterated their buy rating on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a report ...

Stem cell therapy has emerged as a groundbreaking treatment option for corneal injuries, offering hope to individuals ...

After hours: March 17 at 6:14:47 PM EDT Loading Chart for TSHA ...

Investment analysts at Citigroup began coverage on shares of Avidity Biosciences (NASDAQ:RNA – Get Free Report) in a research ...